We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Liquid Biopsy Test Accurately Detects Cancer in Nonsymptomatic Individuals

By LabMedica International staff writers
Posted on 06 Aug 2020
A liquid biopsy test that analyzes levels of circulating tumor DNA methylation detected cancer in nonsymptomatic individuals up to four years before tumors were found by current diagnostic methods.

An international team of investigators at the University of California, San Diego (USA), Fudan University (Shanghai, China), and at the biotech company Singlera Genomics (La Jolla, CA, USA) developed PanSeer, a blood-based cancer screening test that interrogates cancer-specific methylation signatures,

PanSeer reduces the level of noise that frequently interferes with this type of assay by looking for distinct tumor-specific methylation patterns in adjacent methylation sites. More...
This ctmDNA (circulating tumor methylated DNA) technology interrogates over 12,000 methylation marker patterns, and noise is reduced further by employing a highly efficient targeted sequencing library construction method.

The investigators worked with plasma samples collected between 2007 and 2017 from over 120,000 individuals as part of the Taizhou Longitudinal Study. For the current study, they used the PanSeer method to analyze plasma samples obtained from 605 asymptomatic individuals, 191 of whom were later diagnosed with cancer. They also profiled plasma samples from an additional 223 diagnosed cancer patients as well as 200 primary tumor and normal tissue samples.

Results revealed that PanSeer detected five common types of cancer (stomach, esophageal, colorectal, lung, or liver cancer) in 88% of post-diagnosis patients with a specificity of 96%. Overall, PanSeer identified cancers in 91% of samples from individuals who had been asymptomatic when the samples were collected and were only diagnosed with cancer one to four years later. In addition, the method recognized 95% of cancer-free samples.

"The ultimate goal would be performing blood tests like this routinely during annual health checkups," said contributing author Dr. Kun Zhang, professor of bioengineering at the University of California, San Diego. "But the immediate focus is to test people at higher risk, based on family history, age or other known risk factors."

The PanSeer study was published in the July 21, 2020, online edition of the journal Nature Communications.

Related Links:
University of California, San Diego
Fudan University
Singlera Genomics



Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.